VERTEX PHARMACEUTICALS INC / MA Interest Expense
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Interest Expense of $16.29 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA interest expense for the quarter ending 2020-12-31 was $16.29M, a 14.31% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense for the quarter ending 2020-09-30 was $13.86M, a 4.76% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense for the quarter ending 2020-06-30 was $13.87M, a 6.51% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense for the quarter ending 2020-03-31 was $14.14M, a 4.92% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense for fiscal 2020 was $58.15M, a 0.60% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA interest expense for fiscal 2019 was $58.50M, a 19.28% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA interest expense for fiscal 2018 was $72.47M, a 4.58% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA interest expense for fiscal 2017 was $69.30M.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $16.29M 10-K · filed 2021-02-11 | $30.14M derived: sum of 2 quarters · filed 2021-02-11 | $44.02M derived: sum of 3 quarters · filed 2021-02-11 | $58.15M 10-K · filed 2021-02-11 | |
| 2020-09-30 | $13.86M 10-K · filed 2021-02-11 | $27.73M derived: sum of 2 quarters · filed 2021-02-11 | $41.86M derived: sum of 3 quarters · filed 2021-02-11 | $56.11M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2020-06-30 | $13.87M 10-K · filed 2021-02-11 | $28.01M derived: sum of 2 quarters · filed 2021-02-11 | $42.26M derived: sum of 3 quarters · filed 2021-02-11 | $56.80M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2020-03-31 | $14.14M 10-K · filed 2021-02-11 | $28.39M derived: sum of 2 quarters · filed 2021-02-11 | $42.93M derived: sum of 3 quarters · filed 2021-02-11 | $57.77M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-12-31 | $14.25M 10-K · filed 2021-02-11 | $28.80M derived: sum of 2 quarters · filed 2021-02-11 | $43.63M derived: sum of 3 quarters · filed 2021-02-11 | $58.50M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $14.55M 10-K · filed 2021-02-11 | $29.39M derived: sum of 2 quarters · filed 2021-02-11 | $44.25M derived: sum of 3 quarters · filed 2021-02-11 | $63.00M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $14.84M 10-K · filed 2021-02-11 | $29.70M derived: sum of 2 quarters · filed 2021-02-11 | $48.45M derived: sum of 3 quarters · filed 2021-02-11 | $67.14M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | $14.87M 10-K · filed 2021-02-11 | $33.61M derived: sum of 2 quarters · filed 2021-02-11 | $52.30M derived: sum of 3 quarters · filed 2021-02-11 | $70.45M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | $18.74M 10-K · filed 2020-02-13 | $37.43M derived: sum of 2 quarters · filed 2020-02-13 | $55.59M derived: sum of 3 quarters · filed 2020-02-13 | $72.47M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $18.69M 10-K · filed 2020-02-13 | $36.84M derived: sum of 2 quarters · filed 2020-02-13 | $53.73M derived: sum of 3 quarters · filed 2020-02-13 | ||
| 2018-06-30 | $18.16M 10-K · filed 2020-02-13 | $35.04M derived: sum of 2 quarters · filed 2020-02-13 | |||
| 2018-03-31 | $16.89M 10-K · filed 2020-02-13 | ||||
| 2017-12-31 | $69.30M 10-K · filed 2020-02-13 | ||||
| 2012-12-31 | $33.00K 10-K · filed 2014-02-11 | $3.79M 10-K · filed 2013-03-01 | $20.00K derived: sum of 2 quarters · filed 2014-02-11 | -$159.00K derived: sum of 3 quarters · filed 2014-02-11 | $16.65M 10-K · filed 2013-03-01 |
| 2012-09-30 | -$13.00K 10-K · filed 2014-02-11 | $4.56M 10-Q · filed 2012-11-06 | -$192.00K derived: sum of 2 quarters · filed 2014-02-11 | $12.86M 10-Q · filed 2012-11-06 | $12.09M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$179.00K 10-K · filed 2014-02-11 | $4.20M 10-Q · filed 2012-08-08 | $8.30M 10-Q · filed 2012-08-08 | $12.10M derived: sum of 3 quarters · filed 2014-02-11 | $19.16M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | -$150.00K 10-K · filed 2014-02-11 | $4.11M 10-Q · filed 2012-05-10 | $12.28M derived: sum of 2 quarters · filed 2014-02-11 | $19.34M derived: sum of 3 quarters · filed 2014-02-11 | $26.30M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $12.43M 10-K · filed 2013-03-01 | $19.49M derived: sum of 2 quarters · filed 2013-03-01 | $26.45M derived: sum of 3 quarters · filed 2013-03-01 | $38.45M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $7.06M 10-K · filed 2013-03-01 | $14.02M derived: sum of 2 quarters · filed 2013-03-01 | $26.02M 10-Q · filed 2012-11-06 | $33.71M derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-06-30 | $6.96M 10-K · filed 2013-03-01 | $18.96M 10-Q · filed 2012-08-08 | $26.65M derived: sum of 3 quarters · filed 2013-03-01 | $30.60M derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-03-31 | $12.00M 10-K · filed 2013-03-01 | $19.69M derived: sum of 2 quarters · filed 2013-03-01 | $23.64M derived: sum of 3 quarters · filed 2013-03-01 | $27.32M derived: sum of 4 quarters · filed 2013-03-01 | |
| 2010-12-31 | $7.69M 10-K · filed 2012-02-22 | $11.64M derived: sum of 2 quarters · filed 2012-02-22 | $15.32M derived: sum of 3 quarters · filed 2012-02-22 | $19.27M 10-K · filed 2013-03-01 | |
| 2010-09-30 | $3.95M 10-K · filed 2012-02-22 | $7.63M derived: sum of 2 quarters · filed 2012-02-22 | $11.59M 10-Q · filed 2011-11-03 | $16.15M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-06-30 | $3.68M 10-K · filed 2012-02-22 | $7.64M 10-Q · filed 2011-08-09 | $12.20M derived: sum of 3 quarters · filed 2012-02-22 | $14.13M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-03-31 | $3.96M 10-K · filed 2012-02-22 | $8.52M derived: sum of 2 quarters · filed 2012-02-22 | $10.44M derived: sum of 3 quarters · filed 2012-02-22 | $13.77M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2009-12-31 | $4.56M 10-K · filed 2011-02-17 | $6.49M derived: sum of 2 quarters · filed 2011-02-17 | $9.81M derived: sum of 3 quarters · filed 2011-02-17 | $13.19M 10-K · filed 2012-02-22 | |
| 2009-09-30 | $1.93M 10-K · filed 2011-02-17 | $5.25M derived: sum of 2 quarters · filed 2011-02-17 | $8.63M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $3.33M 10-K · filed 2011-02-17 | $6.70M 10-Q · filed 2010-08-03 | |||
| 2009-03-31 | $3.38M 10-K · filed 2011-02-17 | ||||
| 2008-12-31 | $13.47M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |